REGISTERED NUMBER: 16037204 (England and Wales)

PULSEWAVE MEDICAL LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 23 OCTOBER 2024 TO 31 JANUARY 2026

Page

Balance Sheet

1

FIXED ASSETS

599

CURRENT ASSETS

393,437

CREDITORS

Amounts falling due within one year

(98,800

)

NET CURRENT ASSETS

294,637

TOTAL ASSETS LESS CURRENT LIABILITIES

295,236

CAPITAL AND RESERVES

295,236

NOTES TO THE FINANCIAL STATEMENTS

1.	STATUTORY INFORMATION

Pulsewave Medical Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

16037204

Registered office:

7 Sandy Court

Ashleigh Way

Langage Business Park

Plymouth

Devon

PL7 5JX

The presentation currency of the financial statements is the Pound Sterling (£).

2.	AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the period was 2 .

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 January 2026.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 January 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 13 July 2026 and were signed on its behalf by:

N Bellenger - Director